Precision Medicine in Oncology®

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Nimmi S. Kapoor, MD, surgical oncologist, Breastlink Laguna Hills and Breastlink Orange, discusses the benefits and safety of multigene panel testing in patients who are at risk for hereditary breast cancer.

Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes and stromal-infiltrating lymphocytes in patients with triple-negative breast cancer (TNBC).

More than half of brain metastases harbored clinically actionable genetic alterations that were distinct from those associated with the primary tumor.

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

Mismatch repair deficiency may serve as an immuno-oncology biomarker and may illustrate the clinical utility of analyzing the number of mutations per tumor.

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.